Despite the establishment of OFS as a part of standard-of-care adjuvant therapy for premenopausal women with hormone receptor–positive BC at high risk of recurrence, guidance on the practical administration and monitoring of it is limited. The gene discussed is NR4A1; the disease is breast cancer.